Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) have been assigned a consensus rating of “Hold” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $5.00.
Separately, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, December 27th.
An institutional investor recently bought a new position in AcelRx Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 59,184 shares of the specialty pharmaceutical company’s stock, valued at approximately $120,000. Virtu Financial LLC owned 0.12% of AcelRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 9.20% of the company’s stock.
Shares of AcelRx Pharmaceuticals (ACRX) traded down $0.03 during trading on Friday, reaching $2.05. 121,195 shares of the company’s stock were exchanged, compared to its average volume of 435,496. The company has a market cap of $101.80, a price-to-earnings ratio of -1.82 and a beta of 2.58. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a debt-to-equity ratio of -0.31, a quick ratio of 4.57 and a current ratio of 4.64.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). The firm had revenue of $0.74 million during the quarter, compared to the consensus estimate of $2.90 million. sell-side analysts expect that AcelRx Pharmaceuticals will post -0.98 earnings per share for the current year.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.